MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 524107 | Name: ABT 491 Hydrochloride

Description:

WARNING: This product is for research use only, not for human or veterinary use.

ABT-491 hydrochloride is a highly potent, selective and orally active platelet-activating factor receptor (PAF-R) antagonist.

Chemical Structure

ABT 491 Hydrochloride
ABT 491 Hydrochloride
CAS#189689-94-9

Theoretical Analysis

MedKoo Cat#: 524107

Name: ABT 491 Hydrochloride

CAS#: 189689-94-9

Chemical Formula: C28H23ClFN5O2

Exact Mass:

Molecular Weight: 515.97

Elemental Analysis: C, 65.18; H, 4.49; Cl, 6.87; F, 3.68; N, 13.57; O, 6.20

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
ABT 491 hydrochloride; ABT 491; ABT-491; ABT491;
IUPAC/Chemical Name
1H-Indole-1-carboxamide, 4-ethynyl-3-(3-fluoro-4-((2-methyl-1H-imidazo(4,5-c)pyridin-1-yl)methyl)benzoyl)-N,N-dimethyl-, monohydrochloride
InChi Key
AWRGBOKANQBIBM-UHFFFAOYSA-N
InChi Code
InChI=1S/C28H22FN5O2.ClH/c1-5-18-7-6-8-25-26(18)21(16-34(25)28(36)32(3)4)27(35)19-9-10-20(22(29)13-19)15-33-17(2)31-23-14-30-12-11-24(23)33;/h1,6-14,16H,15H2,2-4H3;1H
SMILES Code
O=C(N1C=C(C(C2=CC=C(CN3C(C)=NC4=C3C=CN=C4)C(F)=C2)=O)C5=C1C=CC=C5C#C)N(C)C.[H]Cl
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 515.97 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Xu B, Gao L, Wang L, Tang G, He M, Yu Y, Ni X, Sun Y. Effects of platelet-activating factor and its differential regulation by androgens and steroid hormones in prostate cancers. Br J Cancer. 2013 Sep 3;109(5):1279-86. doi: 10.1038/bjc.2013.480. Epub 2013 Aug 15. PubMed PMID: 23949154; PubMed Central PMCID: PMC3778313. 2: Keating FK, Schneider DJ. The influence of platelet activating factor on the effects of platelet agonists and antiplatelet agents in vitro. J Thromb Thrombolysis. 2009 Jul;28(1):38-45. doi: 10.1007/s11239-008-0239-5. Epub 2008 Jun 25. PubMed PMID: 18574670. 3: Bozlu G, Atici A, Turhan AH, Polat A, Nayci A, Okuyaz C, Taskinlar H. Platelet-activating factor antagonist (ABT-491) decreases neuronal apoptosis in neonatal rat model of hypoxic ischemic brain injury. Brain Res. 2007 Apr 27;1143:193-8. Epub 2007 Feb 1. PubMed PMID: 17320823. 4: Reyes YA, Shimoyama T, Akamatsu H, Sunamori M. MCI-186 (edaravone), a free radical scavenger, attenuates ischemia-reperfusion injury and activation of phospholipase A(2) in an isolated rat lung model after 18 h of cold preservation. Eur J Cardiothorac Surg. 2006 Mar;29(3):304-11. Epub 2006 Jan 19. PubMed PMID: 16427299. 5: Curtin ML, Davidsen SK, Heyman HR, Garland RB, Sheppard GS, Florjancic AS, Xu L, Carrera GM Jr, Steinman DH, Trautmann JA, Albert DH, Magoc TJ, Tapang P, Rhein DA, Conway RG, Luo G, Denissen JF, Marsh KC, Morgan DW, Summers JB. Discovery and evaluation of a series of 3-acylindole imidazopyridine platelet-activating factor antagonists. J Med Chem. 1998 Jan 1;41(1):74-95. PubMed PMID: 9438024. 6: Albert DH, Malo PE, Tapang P, Shaughnessy TK, Morgan DW, Wegner CD, Curtin ML, Sheppard GS, Xu L, Davidsen SK, Summers JB, Carter GW. The role of platelet-activating factor (PAF) and the efficacy of ABT-491, a highly potent and selective PAF antagonist, in experimental allergic rhinitis. J Pharmacol Exp Ther. 1998 Jan;284(1):83-8. PubMed PMID: 9435164. 7: Albert DH, Tapang P, Morgan DW, Curtin ML, Sheppard GS, Davidsen SK, Summers JB, Carter GW. ABT-491, a highly potent and selective PAF antagonist, inhibits nasal vascular permeability associated with experimental allergic rhinitis in brown Norway rats. Inflamm Res. 1997 Aug;46 Suppl 2:S133-4. PubMed PMID: 9297547. 8: Albert DH, Magoc TJ, Tapang P, Luo G, Morgan DW, Curtin M, Sheppard GS, Xu L, Heyman HR, Davidsen SK, Summers JB, Carter GW. Pharmacology of ABT-491, a highly potent platelet-activating factor receptor antagonist. Eur J Pharmacol. 1997 Apr 23;325(1):69-80. PubMed PMID: 9151941.

View History

Sulfo-Cy3 NHS ester

Sulfo-Cy3 NHS ester

Featured